Ocular toxoplasmosis: Advances in detection and treatment

International Ophthalmology Clinics

Volumn 51, Issue 4, 2011, Pages 13-23

  Englander, Miriam ^a   Young, Lucy H Y ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ATOVAQUONE; AZITHROMYCIN; BEVACIZUMAB; CLINDAMYCIN; CORTICOSTEROID; FOLINIC ACID; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PROTOZOON ANTIBODY; PYRIMETHAMINE; SPIRAMYCIN; STEROID; SULFADIAZINE; SULFAMETHOXAZOLE; SULFONAMIDE; TOXOPLASMA GONDII VACCINE; TRIMETHOPRIM; VERTEPORFIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY DETECTION; ARTICLE; BIOPSY; BLINDNESS; BLOOD CELL COUNT; BLOOD EXAMINATION; BLOOD TRANSFUSION; BRADYZOITE; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID; CHORIORETINITIS; CONGENITAL INFECTION; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; ENCEPHALITIS; EPIRETINAL MEMBRANE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; GENOME; GROWTH RETARDATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INDOCYANINE GREEN ANGIOGRAPHY; LASER COAGULATION; LEUKOPENIA; MATERNAL DISEASE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NEEDLESTICK INJURY; NONHUMAN; OOCYTE; OPTICAL COHERENCE TOMOGRAPHY; ORGAN TRANSPLANTATION; PARASITE TRANSMISSION; PARS PLANA VITRECTOMY; PATHOGENESIS; PATIENT COMPLIANCE; PLACENTAL TRANSFER; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RETINA DETACHMENT; RETINA EDEMA; RETINA MACULA CYSTOID EDEMA; SMEAR; SUBRETINAL NEOVASCULARIZATION; SYSTEMATIC REVIEW (TOPIC); TACHYZOITE; THROMBOCYTOPENIA; TOXOPLASMA GONDII; TOXOPLASMOSIS; UNSPECIFIED SIDE EFFECT; UVEITIS; VASCULITIS; VISUAL ACUITY; VITRECTOMY; VITREORETINOPATHY; VITREOUS HEMORRHAGE; VITREOUS OPACITY;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIPROTOZOAL AGENTS; DIAGNOSIS, DIFFERENTIAL; DNA, PROTOZOAN; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; HUMANS; INCIDENCE; LASER COAGULATION; POLYMERASE CHAIN REACTION; PROGNOSIS; TOMOGRAPHY, OPTICAL COHERENCE; TOXOPLASMA; TOXOPLASMOSIS, OCULAR; UNITED STATES;

EID: 80052733252     PISSN: 00208167     EISSN: 15369617     Source Type: Journal    
DOI: 10.1097/IIO.0b013e31822d663b     Document Type: Article

References (90)

1. Holland GN. Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course ofdisease. Am J Ophthalmol. 2003;136:973-988. (Pubitemid 37485762)
2. Jones J, Kruszon-Moran D, Wilson M, et al. Toxoplasma gondii infection in the United States. Am J Epidemiol. 2001;154:357-365.
3. Glasner PD, Silveira C, kruszon-Moran D, et al. An unusually high prevalence of ocular toxoplasmosis in southern Brazil. Am J Ophthalmol. 1992;114:136-144.
4. Silveira C, Belfort R Jr, Burnier M, et al. Acquired toxoplasmosis infection as the cause of toxoplasmic retinichoroiditis in families. Am J Ophthalmol. 1988;106: 362-364.
5. Matos K, Muccioli C, Belfort R Jr, et al. Correlation between clinical diagnosis and PCR analysis of serum, aqueous, and vitreous samples in patients with inflammatory eye disease. Arq Bras Oftalmol. 2007;70:109-114.
6. De Amorin Garcia CA, Orefice F, de Oliveira Lyra C, et al. Socioeconomic conditions as determining factors in the prevalence of systemic and ocular toxoplasmosis in Northeastern Brazil. Ophthalmic Epidemiol. 2004;11:301-317. (Pubitemid 39576622)
7. Silveira C, Belfort R Jr, Muccioli C, et al. A follow-up study of Toxoplasma gondii infection in southern Brazil. Am J Ophthalmol. 2001;131:351-354. (Pubitemid 32184521)
8. Gilbert RE, Freeman K, Lago EG, et al, for the European Multicenter Study on Congenital Toxoplasmosis (EMSCOT). Ocular sequel of congenital toxoplasmosis in Brazil compared with Europe. PLo S Negl Trop Dis. 2008;2:e277.
9. Chacin-Bonilla L, Sanchez-Chavez Y, Monsalve F, et al. Seroepidemiology of toxoplas-mosis in Amerindians from Western Venezuela. Am J Trop Med Hyg. 2001;65:131-135. (Pubitemid 32744218)
10. Teutsch S, Juranek DD, Sulzer A, et al. Epidemic toxoplasmosis associated with infected cats. N Engl J Med. 1979;300:695-699. (Pubitemid 9154805)
11. Bowie W, King AS, Werker DH, et al. Outbreak of toxoplasmosis associated with municipal drinking water. Lancet. 1997;350:173-177. (Pubitemid 27303624)
12. Bahia-Oliveiria L, Jones JL, Azevedo-Silva J, et al. Highly endemic, waterborne toxoplasmosis in north Rio de Janeiro state, Brazil. Emerg Infect Dis. 2003;9:55-62. (Pubitemid 36110203)
13. Brooks R, Remington JS. Transplant-related infections. In: Bennett JV, Brachman PS, eds. Hospital Infections. 2nd ed.Boston: Little, Brown and Co.; 1985:581-618.
14. Raisanen S. The importance oftrophozoites in transmission oftoxoplasmosis: survival and pathogenity of Toxoplasma gondii trophozoites in liquid media. Med Hypotheses. 1978;4:367-375. (Pubitemid 9015469)
15. Remington J, Gentry LO. Acquired toxoplasmosis: infection versus disease. Ann N Y Acad Sci. 1970;174:1006-1017.
16. Remington J, Mc Leod R, Thulliez P, et al. Infectious Diseases of the Fetus and Newborn Infant. 5th ed.Philadelphia: WB. Saunders; 2001: 205-346.
17. Wilson C, Remington JS, Stagno S, et al. Development ofadverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics. 1980;66:767-774. (Pubitemid 11250438)
18. Montoya J, Liesenfeld O. Toxoplasmosis. Lancet. 2004;363:1965-1976. (Pubitemid 38759657)
19. Holland GN. Reconsidering the pathogenesis of ocular toxoplasmosis. Am J Ophthalmol. 1999;128:502-505. (Pubitemid 29479326)
20. Roberts F Mets MB, Ferguson DJ, et al. Histopathological features of ocular toxoplasmosis in the fetus and infant. Arch Ophthalmol. 2001;119:51-58. (Pubitemid 32096385)
21. Muino J, Juarez CP, Luna JD, et al. The importance of specific Ig G and Ig E autoantibodies to retinal S antigen, total serum Ig E, and s CD23 levels in autoimmune and infectious uveitis.J Clin Immunol. 1999;19:215-222. (Pubitemid 29409450)
22. Bosch-Driessen L, Berendschot TT, Ongkosuwito JV, et al. Ocular toxoplasmosis: clinical features and prognosis of 154 patients. Ophthalmology. 2002;109:869-878. (Pubitemid 34465218)
23. Holland GN, Lewis KG. An update on current practices in the management ofocular toxoplasmosis. Am J Ophthalmol. 2002;134:102-114. (Pubitemid 34722718)
24. Perkins E. Ocular toxoplasmosis. Br J Ophthalmol. 1973;57:1-17.
25. Wallace G. Serologic and epidemiologic observations on three Pacific atolls. Am J Epidemiol. 1969;90:103-111.
26. Montoya J, Reminton JS. Toxoplasmic chorioretinitis in the setting ofacute acquired toxoplasmosis. Clin Infect Dis. 1996;23:277-282. (Pubitemid 26264909)
27. Ongkosuwito J, Bosch-Driessen EH, Kijlstra A, et al. Serologic evaluation ofpatients with primary and recurrent ocular toxoplasmosis for evidence of infection. Am J Ophthalmol. 1999;128:407-412. (Pubitemid 29481040)
28. Burnett A, Sortt SG, Issac-Renton J, et al. Multiple cases of acquired toxoplasmosis retinitis presenting in an outbreak. Ophthalmology. 1998;105:1032-1037. (Pubitemid 28268327)
29. Glasner P, Silveira C, Kruszon-Moran D, et al. An unusually high prevalence ofocular toxoplasmosis in southern Brazil. Am J Ophthalmol. 1992;114:136-144.
30. Sibalic D, Djurkovic-Djakovic O, Bobic B. Onset ofocular complications in congenital toxoplasmosis associated with immunoglobulin M antibodies to Toxoplasma gondii. Eur J Microbiol. 1990;9:671-674. (Pubitemid 20311756)
31. Francis JM, Joynson DH. Duration of specific immunoglobulin A antibody following acute toxoplasmosis as determined by enzyme immunoassay and immunosorbent agglutination assay. Eur J Clin Microbiol Infect Dis. 1993;12:556-559. (Pubitemid 23241809)
32. Gaete MIL, Malaguenio E, Cordeiro F, et al. Relacao entre Ig A excretora na lagrima X Ig A serica na toxoplasmose ocular com lesao ativa. Dissertacao de Mestrado defendida em junho de 2003 pela UFPE (Universidade federal de Pernambuco), 2007-03-08.
33. Wilson M, Remington JS, Clavet C, et al. Evaluation of six commercial kits for detection of human immunoglobulin M antibodies to Toxoplasma gondii: the FDA Toxoplasmosis Ad Hoc Working Group.J Clin Microbiol. 1997;35:3112-3115. (Pubitemid 27505729)
34. Pietkiewicz H, Hiszczyńska-Sawicka E, Kur J, et al. Usefulness of Toxoplasma gondii-specific recombinant antigens in serodiagnosis of human toxoplasmosis. J Clin Microbiol. 2004;42:1779-1781. (Pubitemid 38500839)
35. Chen M, Aosai F Mun HS, et al. Correlation between the avidity maturation of anti-HSP70 Ig G autoantibody and recombination activating gene expressions in peri-pheral lymphoid tissues of Toxoplasma gondii-infected mice. Microbiol Immunol. 2003;47:217-221. (Pubitemid 36362446)
36. Suzuki LA, Rocha RJ, Rossi CL. Evaluation of serological markers for the immunodiagnosis of acute acquired toxoplasmosis. J Med Microbiol. 2001 50:62-70. (Pubitemid 32042808)
37. Su C, Shwab EK, Zhou P, et al. Moving towards an integrated approach to molecular detection and identification of Toxoplasmagondii. Parasitology. 2010;7:1-11. Epub 2009 Sep 21.
38. Bell A, Ranford-Cartwright L. Real-time quantitative PCR in parasitology. Trends Parasitol. 2002;18:337-342.
39. Contini C, Seraceni S, Cultrera R, et al. Evaluation of a Real-time PCR-based assay using the lightcycler system for detection of Toxoplasma gondii bradyzoite genes in blood specimens from patients with toxoplasmicretinochoroiditis. Int J Parasitology. 2005;35:275-283. (Pubitemid 40250211)
40. Calderaro A, Piccolo G, Gorrini C, et al. Comparison between two real-time PCR assays and a nested-PCR for the detection of Toxoplasma gondii. Acta Bio Med. 2006;77:75-80.
41. Blackston CR, Dubey JP, Dotson E, et al. High-resolution typing of Toxoplasma gondii using microsatellite loci. J Parasitol. 2001;87:1472-1475. (Pubitemid 34013836)
42. Hurtado A, Aduriz G, Moreno B, et al. Single tube nested PCR for the detection of Toxoplasma gondii in fetal tissues from naturally aborted ewes. Vet Parasitol. 2001;102:17-27. (Pubitemid 33052430)
43. Jauregui LH, Higgins J, Zarlenga D, et al. Development of a real-time PCR assay for detection of Toxoplasma gondii in pig and mouse tissues. J Clin Microbiol. 2001;39: 2065-2071. (Pubitemid 32531460)
44. Lin MH, Chen TC, Kuo T, et al. Real-time PCR for quantitative detection of Toxoplasma gondii. J Clin Microbiol. 2000;38:4121-4125. (Pubitemid 32233214)
45. Sterkers Y, Varlet-Marie E, Cassaing S, et al. Multicentric comparative analytical performance study for molecular detection of low amounts of Toxoplasma gondii from simulated specimens.J Clin Microbiol. 2010;48:3216-3222.
46. Kasper DC, Sadeghi K, Prusa A-R, et al. Quantitative real-time polymerase chain reaction for the accurate detection of Toxoplasma gondii in amniotic fluid. Diagn Microbiol Infect Dis. 2009;63:10-15.
47. Wallon M, Dunn D, Slimani D, et al. Diagnosis ofcongenital toxoplasmosis at birth: what is the value oftesting for Ig M and Ig A Eur. J Pediatr. 1999;158:645-649. (Pubitemid 29331033)
48. Lebech M,Joynson DH, Seitz HM, et al. Classification system and case definitions of Toxoplasma gondii infection in immunocompetent pregnant women and their congenitally infected offspring. Eur J Clin Microbiol Infect Dis. 1996;15:799-805. (Pubitemid 26386122)
49. Ciardelli L, Meroni V, Avanzini MA, et al. Early and accurate diagnosis ofcongenital toxoplasmosis. Pediatr Infect Dis J. 2008;27:125-129.
50. Fatoohi AF, Cozon GJ, Wallon M, et al. Cellular immunity to Toxoplasma gondii in congenitally infected newborns and immunocompetent infected hosts. Eur J Clin Microbiol Infect Dis. 2003;22:181-184. (Pubitemid 36461368)
51. Chapey E, Wallon M, Debize G, et al. Diagnosis ofcongenital toxoplasmosis by using a whole-blood gamma interferon release assay.J Clin Microbiol. 2010;48:41-45.
52. Lau YL, Meganathan P, Sonaimuthu P, et al. Specific, sensitive, and rapid diagnosis of active toxoplasmosis by a loop-mediated isothermal amplification method using blood samples from patients.J Clin Microbiol. 2010;48:3698-3702.
53. Gallagher MJ, Yilmaz T, Cervantes-Castañeda RA, et al. The characteristic features of optical coherence tomography in posterior uveitis. Br J Ophthalmol. 2007;91: 1680-1685. (Pubitemid 350207399)
54. Garg S, Mets MB, Bearelly S, et al. Imaging ofcongenital toxoplasmosis macular scars with optical coherence tomography. Retina. 2009;29:631-637.
55. Stanford M, See SE, Jones LV, et al. Antibiotics for toxoplasmic retinochoroiditi. Ophthalmology. 2003;110:926-932.
56. Dodds EM. Ocular Toxoplasmosis: Clinical Presentation, Diagnosis and Therapy. Focal Points: Clin Modules Ophthalmol Vol XVII. San Francisco: American Academy of Ophthalmology; 1999:10.
57. Rothova A, Meenken C, Buitenhuis HJ, et al. Therapy for ocular toxoplasmosis. Am J Ophthalmol. 1993;115:517-523. (Pubitemid 23109806)
58. Soheilian M, Sadoughi MM, Ghajarnia M, et al. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treat-ment ofocular toxoplasmosis. Ophthalmology. 2005;112:1876-1882.
59. Bosch-Driessen LH, Verbraak FD, Suttorp-Schulten MS, et al. A prospective, random-ized trial ofpyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment ofocular toxoplasmosis. Am J Ophthalmol. 2002;134:34-40. (Pubitemid 34722707)
60. Gormley P, Pavesio CE, Minnasian D, et al. Effects ofdrug therapy on toxoplasma cysts in an animal model of acute and chronic disease. Invest Ophthalmol Vis Sci. 1998;39:1171-1175. (Pubitemid 28247351)
61. Dumas J, Chang R, Mermillod B, et al. Evaluation of the efficacy of prolonged administration of azithromycin in a murine model of chronic toxoplasmosis. JAntimicrob Chemother. 1994;34:111-118. (Pubitemid 24237599)
62. Martinez CE, Zhang D, Conway MD, et al. Successful management of ocular toxoplasmosis during pregnancy using combined intraocular clindamycin and dexamethasone with systemic sulfadiazine. Int Ophthalmol. 1998;22:85-88. (Pubitemid 29396302)
63. Garweg JG, Scherrer JN, Halberstad M. Recurrence characteristics in European patients with ocular toxoplasmosis. BJO. 2008;92:1253-1256.
64. Bosch-Driessen L, Berendschot T, Ongkosuwito J, et al. Ocular toxoplasmosis\- clinical features and prognosis of 154 patients. Ophthalmology. 2002;109:869-878. (Pubitemid 34465218)
65. Winterhalter S, Severing K, Stammen J, et al. Does atovaquone prolong the disease-free interval of toxoplasmic retinochoroiditis? Graefes Arch Clin Exp Ophthalmol. 2010;248:1187-1192.
66. Kishore K, Conway MD, Peyman GA. Intravitreal clindamycin and dexamethasone for toxoplasmic retinochoroiditis. Ophthalmic Surg Lasers. 2001;32:183-192.
67. Lasave AF, D́az-Llopis M, Muccioli C, et al. Intravitreal clindamycin and dexametha-sone for zone 1 toxoplasmic retinochoroiditis at twenty-four months. Ophthalmology. 2010;117:1831-1838.
68. Soheilian M, Ramezani A, Azimzadeh A, et al. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and predniso-lone in treatment ofocular toxoplasmosis. Ophthalmology. 2010; Aug:11.
69. Garcia-Méric P, Franck J, Dumon H, et al. Management of congenital toxoplasmosis in France: current data. Presse Med. 2010;39:530-538.
70. Thiébaut R, Leproust S, Chêne G, et al. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. Lancet. 2007;369:115-122.
71. Holland GN, Engstrom RE, Glasgow BJ, et al. Ocular toxoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol. 1988;106: 653-667. (Pubitemid 19009919)
72. Schürmann D, Bergmann F, Albrecht H, et al. Effectiveness of twice-weekly pyrimethamine-sulfadoxine as primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in patients with advanced HIV infection. Eur J Clin Microbiol Infect Dis. 2002;21:353-361. (Pubitemid 34810670)
73. Bucher HC, Griffith L, Guyatt GH, et al. Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. JAcquir Immune Defic Syndr Hum Retrovirol. 1997;15:104-114.
74. Podzamczer D, Salazar A, Jiménez J, et al. Intermittent trimethoprim-sulfamethox-azole compared with dapsone-pyrimethamine for the simultaneous primary prophy-laxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med. 1995;122:755-761.
75. Rodriguez A. Photocoagulation in toxoplasmic retinochoroiditis. Am J Ophthalmol. 1981;91:417-418.
76. Spalter HF, Campbell CJ, Noyori KS, et al. Prophylactic photocoagulation of recurrent toxoplasmic retinochoroiditis: a preliminary report. Arch Ophthalmol. 1966;75:21-31.
77. Adan A, Giralt J, Alvarez G, et al. Pars plana vitrectomy for vitreoretinal complications ofocular toxoplasmosis. Eur J Ophthalmol. 2009;19:1039-1043.
78. Ben Yahia S, Herbort CP, Jenzeri S, et al. Intravitreal bevacizumab (Avastin) as primary and rescue treatment for choroidal neovascularization secondary to ocular toxoplasmosis. Int Ophthalmol. 2008;28:311-316.
79. Buxton D. Toxoplasmosis: the first commercial vaccine. Para sitol Today. 1993;9:335-337. (Pubitemid 23238279)
80. Dubey JP, Urban JF Jr, Davis SW. Protective immunity to toxoplasmosis in pigs vaccinated with a nonpersistent strain of Toxoplasma gondii. Am J Vet Res. 1991;52:1316-1319.
81. Freyre A, Choromanski L, Fishback JL, et al. Immunisation ofcats with tissue cysts, bradyzoites and tachyzoites of the T-263 strain of Toxoplasma gondii. J Parasitol. 1993;79:716-719. (Pubitemid 23333663)
82. Siachoque H, Guzman F, Burgos J, et al. Toxoplasma gondii: immunogenicity and protection by P30 peptides in a murine model. Exp Parasitol. 2006;114:62-65. (Pubitemid 44188651)
83. Yang CD, Chang GN, Chao D. Protective immunity against Toxoplasma gondii in mice induced by a chimeric protein r SAG1/2. Parasitol Res. 2004;92:58-64. (Pubitemid 38167940)
84. Petersen E, Nielsen HV, Christiansen L, et al. Lmmunization with E. coli produced recombinant Tgondii SAG1 with alum as adjuvant protect mice against lethal infection with Toxoplasmagondii. Vaccine. 1998;16:1283-1289. (Pubitemid 28308409)
85. Jongert E, Melkebeek V, De Craeye S, et al. An enhanced GRA1-GRA7 cocktail DNA vaccine primes anti-Toxoplasma immune responses in pigs. Vaccine. 2008;26:1025-1031.
86. Ismael AB, Dimier-Poisson I, Lebrun M, et al. MIC1-3 knockout of Toxoplasma gondii is a successful vaccine against chronic and congenital toxoplasmosis in mice.J Infect Dis. 2006;194:1176-1183. (Pubitemid 44547659)
87. Nielsen HV, Lauemøller SL, Christiansen L, et al. Complete protection against lethal Toxoplasma gondii infection in mice immunized with a plasmid encoding the SAG1 gene.Infect Immun. 1999;67:6358-6363.
88. Angus CW, Klivington-Evans D, Dubey JP, et al. Immunization with a DNA plasmid encoding the SAG1 (P30) protein of Toxoplasmagondii is immunogenic and protective in rodents.JInfect Dis. 2000;181:317-324. (Pubitemid 30049063)
89. Cong H, Gu QM,Jiang Y, et al. Oral immunization with a live recombinant attenuated Salmonella typhimurium protects mice against Toxoplasma gondii. Parasite Immunol. 2005;27:29-35. (Pubitemid 40524990)
90. Qu D, Wang S, Cai W, et al. Protective effect of a DNA vaccine delivered in attenuated Salmonella typhimurium against Toxoplasma gondii infection in mice. Vaccine. 2008;26: 4541-4548.